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Abstract
Background: Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for
the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data
such as adherence to drug-refill visits as early warning indicators. We examined the association between adherence to drug-
refill visits and long-term virologic and immunologic failure among non-nucleoside reverse transcriptase inhibitor (NNRTI)
recipients in South Africa.
Methods: In 2008, 456 patients on NNRTI-based ART for a median of 44 months (range 12–99 months; 1,510 person-years)
were enrolled in a retrospective cohort study in Soweto. Charts were reviewed for clinical characteristics before and during
ART. Multivariable logistic regression and Kaplan-Meier survival analysis assessed associations with virologic (two repeated
VL.50 copies/ml) and immunologic failure (as defined by WHO).
Results: After a median of 15 months on ART, 19% (n=88) and 19% (n=87) had failed virologically and immunologically
respectively. A cumulative adherence of ,95% to drug-refill visits was significantly associated with both virologic and
immunologic failure (p,0.01). In the final multivariable model, risk factors for virologic failure were incomplete adherence
(OR 2.8, 95%CI 1.2–6.7), and previous exposure to single-dose nevirapine or any other antiretrovirals (adj. OR 2.1, 95%CI 1.2–
3.9), adjusted for age and sex. In Kaplan-Meier analysis, the virologic failure rate by month 48 was 19% vs. 37% among
adherent and non-adherent patients respectively (logrank p value=0.02).
Conclusion: One in five failed virologically after a median of 15 months on ART. Adherence to drug-refill visits works as an
early warning indicator for both virologic and immunologic failure.
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Introduction
Antiretroviral treatment (ART) has saved millions of lives by
transforming HIV infection from a fatal into a chronic disease [1]
and the vast majority (97%) of patients in sub-Saharan Africa
receive a non-nucleoside reverse transcriptase (NNRTI) based
regimen as first-line treatment [2]. Given the costs associated with
second-line protease inhibitors, the long-term sustainability of
ART in many of low- and some middle-income countries depends
on finding feasible ways for early detection of treatment failure to
maintain patients on first-line regimens [3,4].
Since viral load (VL) monitoring is not currently accessible in
most resource-limited high-endemic contexts [2,5], patients are
often continued on first-line ART until the emergence of clinical
symptoms or until any of the World Health Organization (WHO)
criteria for immunologic failure are met. Although virologic failure
and drug resistance usually precede immunologic failure, these
measures are not always well correlated at clinical follow-up
[6,7,8]. To routinely assess the effectiveness of ART at HIV
treatment clinics and to minimize preventable HIV drug resistance
(HIVDR), WHO recommends using available site-based data
from medical and pharmacy records, e.g. on-time adherence to
monthly ART drug pick-up and clinic appointment-keeping
[9,10], as an early warning indicator (EWI) of inconsistent drug
exposure. Failure to pick up drugs on time serves as a proxy for
treatment interruption and suboptimal drug concentrations, which
are associated with virologic failure and the evolution of drug
resistance [11,12,13].
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virologic failure as a VL of .400, .1,000 or .5,000 copies/ml
at one or two repeated visits [14,15]. However, drug resistance
mutations can emerge at lower VL levels [16] and in high-income
countries,monitoring guidelines recommend using VL .50 copies/
ml as an indicator of virologic failure for patients on ART [17]. As
more robust, sensitive and lower cost assays are developed, ART
programmes in low- and middle-income may be able to adopt lower
threshold values for virologic failure. Thus, we assessed the
proportion of repeated VL .50 copies/ml, immunologic failure
and median CD4 cell count gains in a cohort of long-term, first-line
recipients in Soweto, who had been on NNTRI-based regimens for
up to eight years. We also assessed the relationship between
cumulative adherence to drug-refill visits and treatment failure.
Methods
Setting and study population
At the time of the study, more than 1,500 patients were receiving
ARTatthisclinic.Aimingforaprecisionof+/25% for a proportion
of 50% using 95% confidence interval, a sample size of 384 patients
was required [18]. Adding a margin to the minimum required sample
size, a cohort of 458 participants on long-term ART (range 12 to 99
months) were enrolled during March-September 2008 [19] for a
cross-sectional assessment and a retrospective review of their medical
charts. The inclusion criteria were: being on NNRTI-containing
regimen for $12 months; consent to an interviewer-mediated
questionnaire; medical record review; and withdrawal of 10ml of
blood. The study, named South African Virologic Evaluation (SAVE)
[15], was performed at the Perinatal HIV Research Unit (PHRU)
adult HIV clinic at the Chris Hani Baragwanath Hospital, in the
Soweto township outside Johannesburg, South Africa. The study site
[20] and a cross-sectional description of viremia and drug resistance
have been described in depth previously [15,21].
Data collection
Patients were interviewed at study enrolment to obtain
demographics, socioeconomic characteristics, reasons for missing
doses and the strategies used to remember taking their pills on
time. The retrospective review included: year of HIV diagnosis;
pre-ART initiation characteristics (VL, CD4 cell count, pre-
exposure to single-dose nevirapine (sdNVP) or other antiretroviral
drugs (ARVs); current and previous TB therapy; dates for drug
refill visits; and treatment interruptions. VL and CD4 counts had
been measured every six months on average. For two of the
patients, medical records were not available and they were
excluded from the longitudinal analysis, leaving 456 patients for
data analyses. A survey form, called Medical Records-SAVE
(MR.SAVE), was developed, piloted and modified [22] for data
collection. EpiData [23,24] was used for data entry.
Definitions
The clinic uses a private diagnostic laboratory service that
provides VL measures with the Versant HIV-1 RNA 3.0 (Siemens
Deerfield, IL, USA) based on bDNA technology, with a lower limit
of detection of 50 copies/ml. Virologic failure was defined as two
repeated VL .50 copies/ml at any time after three months on
ART. Immunologic failure was defined according to the WHO
guidelines as having either (i) a CD4 cell count of ,100 cells/ml
post six months on ART, (ii) a CD4 cell count of less or equal to
CD4 pre-ART after six months on ART or (iii) .50% reduction
from the on-ART peak CD4 cell count [25]. Patients were
dispensed ART monthly and at scheduled doctor’s visits. They
were also given projected monthly pharmacy refill dates and the
date of the next doctor’s appointment. At each refill visit,
pharmacy staff dispensed pills and recorded the date. To estimate
adherence, we calculated the total number of days that the patient
was late for the drug-refill visits divided by the total duration on
ART. The formula was: [The number of days late for drug-refill
visit = (Date when the patient came for drug refill - Date of the
pre-scheduled appointment indicated on the patient’s medical
record)]. The results were then summarized for repeated refill
visits to obtain the cumulative number of days coming late per
client. To estimate adherence, the following formula was used
[The cumulative number of days coming late 6100)/Total
number of days the patient was assumed to be exposed to ART
given the dispensed number of pills]. Appointment dates were
censored after the date of virologic failure.
Incomplete versus complete adherence was defined as a
cumulative adherence to drug refill visits of , and $95%
respectively. Treatment interruption was defined as a reported
and/or planned history of stopping and resuming therapy,
identified through chart review.
Statistical analysis
Descriptive analyses including median (IQR) for numerical
variables, frequencies and proportions for categorical variables
were performed. Bivariate analyses to assess risk factors for
virologic and immunologic failure were performed using Pearson
Chi Square and Fisher’s exact tests. Thereafter variables with a p-
value #0.10 were added into a multivariate logistic regression
model and those with a p-value ,0.05 were considered significant
in the final multivariate model, calculating odds ratios (OR) and
95% confidence intervals (CIs). However, the variables sex and
age were always maintained in the final multivariate models to
account for possible remaining confounders.
Kaplan Meier survival analysis was done using months as the
time unit in order to assess time to virologic and immunologic
failure on ART among all patients.
Known pre-ART risk factors, exposure to sdNVP [26,27,28] or
any type of ARVs, CD4 cell count and age [26,29,30] were
adjusted using Cox regression analysis for virologic failure. For
immunologic failure, Cox regression analysis was done by
adjusting for the same above-mentioned variables and any
virologic failure. Due to collinearity between sex and pre-ART
CD4 count, sex was not included in the final survival model.
Finally, we assessed the median gain in CD4 cell count during
ART on a six-monthly basis (range +/23 months) among 1)
patients with incomplete vs. complete cumulative drug-refill
adherence, and 2) patients with virologic failure vs. suppression
up to 36 months on ART only, due to data availability.
Stata/SE College Station, Texas (version 10.1) [31] and
Graphpad Prism (version 4.0c) [32] were used for data analysis.
In the survival analysis, the command sts graph in STATA was
used. Adjusting for covariates, the command fits separate Cox
regression models for each group, and the separately calculated
baseline survivor was then retrieved.
Ethical approval for this study was obtained from the research
ethics committees at the University of the Witwatersrand in
Johannesburg, South Africa, and the Regional Medical Ethics
Board in Stockholm, Sweden. Written informed consent was
obtained from all patients.
Results and Discussion
Patients’ characteristics
A total of 456 patient records were reviewed. Most patients
(79%) were diagnosed with HIV between 2001-2004 (median
HIV Viremia & Immunologic Failure in South Africa
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e175182003), 14% before 2000 and the remaining 7% between 2005 and
2008. Pre-ART initiation, 51% (222/434) had a CD4 cell count of
#100 cell/ml and 41% (172/421) had a VL of $100 000 copies/
ml (Table 1). Overall, the median time on ART was 44 months
(IQR 38–48; 1,510 person-years) and 77% (349/456) were women
(Table 1). Eighteen percent (80/445) had been exposed to ARVs
previously; 15% of the women (52/349) had received sdNVP for
the prevention of mother-to-child transmission (PMTCT) with a
median time before ART initiation of 15 months, and 6% of all
patients (28/446) had received ART before starting the current
ART regimen. Approximately half (48%, 199/414) had been
treated for tuberculosis (TB) before ART initiation. At the time of
study enrolment, the patients spent a median of 40 minutes (IQR
30–60) travelling to the clinic by mini-van (90%), walking (5%) and
using their own car (4%).
Virologic failure
Overall, 19% (88/456) met the criteria for virologic failure. In
bivariate analysis, being exposed to any type of ARVs including
sdNVP prior to ART initiation or incomplete adherence was
significantly associated with virologic failure (p=0.04) (Table 1a).
These two factors remained significant after adjustment for
confounding by age and sex in the multivariable analysis model.
The odds ratio of virologic failure among patients with incomplete
adherence almost tripled (adjusted OR 2.8, 95%CI 1.2–6.7) and
doubled among those exposed to any type of ARVs prior to ART
initiation (adj. OR 2.1, 95%CI 1.2–3.9). However, exposure to
sdNVP alone did not reach statistical significance. Neither the
level of CD4 cell count nor VL at pre-ART initiation was
significantly associated with subsequent virologic failure on ART
in bivariate analyses, and therefore was not included in the
multivariable model.
In a separate analysis, there was no significant association
between incomplete adherence and any of the patients’ demo-
graphic, socioeconomic or clinical data (not shown).
Planned treatment interruptions were not part of the clinical
guidelines at this clinic. Of the 456 patients, 132 (29%) had a
reported history of treatment interruption registered in their
medical charts, 98% of these (129/132) only once. Three patients
were reported to have experienced treatment interruption twice
but were not found to fail virologically during the study period.
The median duration of treatment interruption was longer among
patients with, compared to those without, virologic failure; 45 days
(IQR 27–97) vs. 36 days (IQR 19–63) respectively, although this
difference was not statistically significant (p=0.12).
AnalysingtheriskofvirologicfailureovertimeusingKaplanMeier
survival analysis, the virologic failure rate was 23% up until month 99
(Figure 1a). There was a significant difference in time to virologic
failure between patients with complete vs. incomplete adherence. By
month 12 on ART, the failure rate was similar (7% vs 8% among
patients with complete and incomplete adherence respectively) but by
month 48, the difference in failure rates had reached statistical
significance between the groups, 19% vs. 37% respectively (logrank p
value=0.02) (Figure 1a). Following adjustment for CD4 cell count,
age and exposure to any ARVs pre-ART initiation in a Cox
regression analysis, there was a significant difference in virologic
failure rates already at month 12 on ART; 2% vs 11%, and at month
48. This difference was even more pronounced, 18% vs. 43%, among
patients with complete vs incomplete adherence respectively (logrank
pv a l u e,0.01) (Figure 1b).
Immunologic failure
Overall, 87/456 (19%) of the patients met one or more of the
definitions of immunologic failure based on CD4 cell count [33].
In bivariate analysis, immunologic failure was associated with
incomplete adherence (p=0.04), gender (p=0.03), and low
education level (p=0.03) (Table 1). However, none of these
variables remained significant in the final multivariate logistic
regression model. More than one third (37%; 32/87) of patients
failing immunologically were also found to be viremic. Among
those with immunologic failure, there was no significant
difference in CD4 cell count or VL, pre-ART initiation,
between the 32 viremic and 55 non-viremic patients (data not
shown).
Kaplan Meier survival analysis demonstrated an overall
immunologic failure rate of 27% by month 48 (Figure 2a). The
risk of immunologic failure was 41% vs 19% among those with
incomplete and complete adherence respectively after 48 months
on ART (logrank p value=0.02). After adjustment for CD4
cell count, age and exposure to any ARVs pre-ART initiation and
for virologic failure in the Cox regression analysis, patients
with incomplete adherence had an immunologic failure rate of
90% at month 48, while the corresponding figure among patients
with complete adherence was only 11% (Figure 2b) (logrank
p value,0.01).
Immunologic response to ART
There was a significant difference in CD4 cell count gain during
ART between patients with complete vs incomplete adherence at
almost all of the clinical visits (p#0.04) (Figure 3). As expected,
patients initiating ART with a CD4 cell count of .100 cells/ml
had a significantly higher median CD4 cell count in comparison to
patients started on ART at a CD4 cell count of #100 cells/ml
throughout the follow-up period (Figure 4). The median CD4 cell
count was also significantly higher among patients with continuous
virologic suppression patients as compared to those with virologic
rebound up to at least three years on ART (months 18, 24, 30 and
36, p#0.03) (Figure 5).
Barriers and facilitators for adherence
When all patients were asked about the reasons for missing pills,
the three main reasons stated were: being away from home (32%);
simply forgetting (20%); and being busy with other things (10%)
(Figure 6). Eleven other reasons were reported but all with a
prevalence of #6%.
Patients used a combination of methods to remember their
medication; mobile phone alarms (49%), relying on their own
memory (49%), a close friend/relative (20%) or a partner (8%) to
remind them, or pill-boxes (1%).
All interviewees denied any intentional non-adherence in order
to maintain eligibility for disability support. This was despite 39%
of the patients reporting that their primary source of financial
support was the social welfare disability grant provided in South
Africa for HIV-infected patients with a CD4 cell count below 200
cells/ml.
Antiretroviral therapy is a life-long undertaking and finding
feasible and affordable means for early detection of treatment
failure is crucial to sustain first-line therapy effectiveness. Our
study found that the estimated proportion of patients failing
virologically was 2–3 times higher among patients who were late
for their drug-refill visits compared to those with an adherence to
drug refill above 95%. This provides evidence that failure to
collect ART may serve as a proxy for reduced drug exposure over
time.
According to WHO [9,10], monitoring the extent to which
ART sites function through EWIs such as adherence to on-time
drug refills is of high priority in order to minimize preventable
HIVDR. The usefulness and importance of the on-time drug refill
HIV Viremia & Immunologic Failure in South Africa
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b) immunologic failure among 456 patients on ART in Soweto, South Africa.














Women 349 (77%) 68 (19%) 59 (17%)
Men 107 (23%) 20 (19%) 0.87 28 (26%) 0.03
Age
18–24 21 (5%) 5 (24%) 0.42 3 (14%) 0.62
25–34 235 (51%) 45 (19%) 46 (20%)
35–44 147 (32%) 24 (16%) 25 (17%)
$45 53 (12%) 14 (26%) 13 (24%)
Marital status
Have partner 265 (58%) 49 (18%) 50 (19%)
Single/no partner at all 191 (42%) 39 (20%) 0.61 37 (19%) 0.89
Born in South Africa
No 17 (4%) 4 (23%) 2 (12%)
Yes 439 (96%) 84 (19%) 0.65 85 (19%) 0.43
Education level
No education or primary schooling 50 (11%) 11 (20%) 0.61 4 (8%)
Secondary or tertiary education level 406 (89%) 77 (19%) 83 (20%) 0.03*
Year diagnosed with HIV
#2000 63 (14%) 10 (16%) 0.79 10 (16%) 0.66
2001–2004 348 (79%) 68 (20%) 70 (20%)
2005–2008 31 (7%) 6 (19%) 5 (16%)
Any type of work
No 283 (65%) 59 (21%) 60 (21%)
Yes 154 (35%) 28 (18%) 0.51 23 (15%) 0.11
Clinical characteristics**
CD4 cell count – pre-ART
#50 122 (28%) 21 (17%) 0.59 26 (21%) 0.52
51–100 100 (23%) 24 (24%) 21 (16%)
101–249 199 (46%) 37 (19%) 31 (16%)
$250 13 (3%) 2 (15%) 3 (23%)
Viral load level – pre-ART (RNA copies/ml)
,5,000 22 (5%) 2 (9%) 0.54 1 (5%) 0.26
5,000–29,999 110 (26%) 23 (21%) 24 (22%)
30,000–99,999 117 (28%) 20 (17%) 24 (21%)
$100,000 172 (41%) 35 (20%) 30 (17%)
Pre-exposure to sdNVP or other type of ARVs
Treatment naı ¨ve 365 (82%) 64 (18%) 72 (20%)
Single dose-nevirapine (sdNVP) 52 (12%) 13 (25%) 0.19 7 (13%) 0.28
Had any ARVs pre-ART initiation
## 28 (6%) 9 (32%) 0.06 6 (21%) 0.83
Treatment experienced (sdNVP or any ARVs) 80 (18%) 22 (28%) 0.04 13 (16%) 0.47
TB therapy
Not treated before ART 215 (52%) 36 (17%) 38 (18%)
Treated before ART 137 (33%) 27 (20%) 0.48 33 (24%) 0.14
Was on TB therapy when started on ART 62 (15%) 11 (18%) 0.85 10 (16%) 0.78
Disclosed HIV status pre-ART
No 35 (8%) 4 (11%) 8 (23%)
Yes 400 (92%) 80 (20%) 0.22 77 (19%) 0.61
HIV Viremia & Immunologic Failure in South Africa
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time. It showed a significant difference in first-year failure rates
(2% vs 11%) among patients with complete adherence vs
incomplete adherence to drug refill already after 12 months on
treatment. This difference became even more visible after 4 years
on ART (18% vs 43% virologic failure rate respectively) adjusting
for CD4 cell count at ART initiation, age and exposure to any
ARVs pre-ART initiation.
The cumulative proportion with virologic failure in our study is
comparable to similar cohorts of long-term ART-recipients in
urban South African townships including other studies from an
urban site in Johannesburg [34], and from Khayelitsha [30].
Similarly high failure rates have also been reported from
Switzerland [35], England [36,37], France, Spain, Germany and
Canada [37].
Apart from ,95% adherence to drug refills, previous exposure
to other ARVs was the only significant risk factor associated with
an increased risk of virologic failure in our multivariable analysis,
supporting ample existing evidence that sdNVP [38,39,40,41] or
other ARVs [42] may predispose to virologic failure and the
emergence of HIVDR mutations among women treated with
NNRTI-based ARVs.
During the first year on ART, CD4 T-cell restoration can be
slow [43], but we found that the rate of CD4 cell count gain up to
36 months on ART was the same regardless of the initial level of
CD4. Thus, patients starting ART with advanced immuno-
suppression and very low CD4 cell counts (,100 cells/ml)
maintained a significantly lower CD4 cell count level throughout
the study period. This put them at risk of increased morbidity for a
number of years post-ART initiation [30,44], and provides further
justification to initiate ART earlier, as embodied in the recent
WHO recommendations [33]. The gain in CD4 cell count was
significantly dependent on high adherence to drug refill and viral
suppression supporting the findings by Bisson and co-workers [45].













Cumulative adherence to on-time drug refill
95-100% 430 (94%) 79 (18%) 78 (18%)
,95% 26 (6%) 9 (35%) 0.04 9 (35%) 0.04
Any treatment interruption
No 324 (71%) 66 (20%) 58 (18%)
Yes
$ 132 (29%) 22 (17%) 0.36 29 (22%) 0.32
*2-sided Fisher exact test;
**All patients were initiated on an NNRTI-based regimen (the majority had efavirenz);
#Two patients (2/458) were excluded due to missing longitudinal data;
‘Two repeated VL .50 copies/ml post-three months on ART;
‘‘WHO criteria for immunologic failure;
##Two patients were exposed to sdNVP and ART, pre-ART initiation, but virologically suppressed.
$Treatment interruption: once for 129 patients and twice for 3 patients.
doi:10.1371/journal.pone.0017518.t001
Table 1. Cont.
Figure 1. (a) Kaplan-Meier survival analysis for time to virologic failure by level of cumulative adherence to drug refill visits. (b) Cox
regression analysis after adjustment for confounding by CD4 cell count, age and being exposed to sdNVP or any ART pre-ART initiation.
doi:10.1371/journal.pone.0017518.g001
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doi:10.1371/journal.pone.0017518.g003
Figure 2. (a) Kaplan-Meier survival analysis for time to immunologic failure, by level of cumulative adherence to drug refill visits.
(b) Cox regression analysis, adjusted for confounding by virologic failure, CD4 cell count, age and being exposed to sdNVP or any ART pre-ART
initiation.
doi:10.1371/journal.pone.0017518.g002
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immunologically were virologically suppressed at clinical assess-
ment. Thus CD4 cell count is a poor predictor of virologic
outcomes [6,7,46,47] and the use of immunological criteria only
for monitoring treatment responses may jeopardize clinical
management.
All study participants in this study had been on ART for at least
12 months, and over 90% had achieved a CD4 cell count of .200
cells/ml. There is an ongoing debate in South Africa where some
have suggested that HIV patients may keep their CD4 counts at
,200 cells/ml by intentionally missing doses [48,49] to retain
eligibility for disability grants. However, this was firmly denied by
our participants, who rather ascribed missing doses to being away
from home or simply forgetting to take their pills. The interesting
fact that half of our patients used their mobile phones as a
medication reminder opens up future opportunities of systematic
adherence support through text reminders since cell phone access
and usage are rapidly increasing throughout sub-Saharan Africa
[50]. Additionally, dispensing ART for more than 30 days at a
time may also reduce the risk of missed doses.
VL measurements are rarely available in most resource-limited
settings and where measured, virologic failure has often been
defined as VL .400, .1,000 or even .5,000 copies/ml
[15,29,30]. In this study, a more sensitive and conservative
definition for virologic failure was used, .50 copies/ml. While the
fact that some patients with intermittent viremia (blips) were
included may cause some concern, 85% (75/88) were confirmed
viremic in two sequential assessments .50 copies/ml. In this
study, we used ,95% as a conservative cut-off point for
incomplete adherence. In early adherence studies, including
unboosted protease inhibitors (PIs), a 95% adherence level was
shown to be associated with high virologic suppression [51], a
greater increase in CD4 cell count, and lower hospitalization rates
[52,53]. More recent studies have indicated that moderate
adherence levels (70–90%) may be enough to achieve acceptable
virologic suppression with antiretroviral regimens containing
boosted PIs or NNRTIs. However, at the 95% level we can be
quite certain that a very small proportion of individuals on
NNRTI are likely to fail virologically [54,55,56]. The aim of the
current study was to look at treatment failure among long-term
recipients of ART, i.e. excluded those with ,12 months of ART
[15]. However, our retrospective assessment of medical charts
went back and traced all virologic failures, including the first year
on treatment, enabling us to assess the risk of failure from
treatment start-up to a maximum follow-up of over 8 years.
However, with this design, we missed those who first failed
virologically and then dropped out of the programme before
reaching 12 months on treatment. Given that a substantial
proportion of patients enrolled in ART in similar urban settings
are expected to drop out early [57], this would lead to an
underestimation of the true virologic failure rate among NNRTI
recipients in the current assessment.
Figure 4. Median CD4 (IQR) for patients initiated on ART, with CD4 # or .100 cells/ml.
doi:10.1371/journal.pone.0017518.g004
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documented treatment interruptions and virologic failure is likely
due to incomplete clinical data since we only had access to
reported interruptions recorded in the medical charts.
In summary, there was a strong association between cumu-
lative reduced adherence to drug-refill visits and both virologic
and immunologic failure. One in five failed virologically,
the majority within the first two years on ART. On-time
ART pick-up appears to be a feasible tool to identify
individuals at risk, and if followed by prompt and targeted
interventions, it could be used to reduce the rate of virologic
failure.
Figure 5. Median CD4 (IQR) for patients who showed virologic failure vs. those who remained suppressed.
doi:10.1371/journal.pone.0017518.g005
Figure 6. Proportion of patients (%) with self-reported reasons for not taking any of their pills in general at study enrolment
(N=458).
doi:10.1371/journal.pone.0017518.g006
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